Movalis (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which reduces the production of prostaglandins—chemical mediators that cause inflammation, pain and fever—thereby providing anti‑inflammatory and analgesic effects.

The appropriate dose of Movalis is individualized by the prescribing healthcare professional based on the specific indication, severity of disease, patient age, renal and hepatic function, and any concomitant medications.

Safety data for meloxicam in pregnancy and lactation are limited. It is generally avoided unless the potential benefit justifies the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their clinician.

To request Movalis, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both meloxicam and ibuprofen belong to the NSAID class, but meloxicam has greater selectivity for COX‑2, which may result in a lower incidence of gastrointestinal irritation at therapeutic doses. Ibuprofen is typically taken multiple times daily, whereas meloxicam’s longer half‑life often allows once‑daily dosing.

Movalis tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight and heat sources to maintain stability.

Movalis is taken orally with a full glass of water. It can be taken with or without food, although taking it with food may reduce occasional stomach discomfort. Swallow the tablet whole; do not crush or chew.

Serious adverse events include gastrointestinal ulceration or bleeding, severe liver injury, acute kidney failure, cardiovascular thrombotic events such as heart attack or stroke, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Prompt medical attention is required if any of these occur.

Movalis should be avoided in individuals with known hypersensitivity to meloxicam or other NSAIDs, active gastrointestinal ulcer or bleeding, severe heart failure, uncontrolled hypertension, and in patients with significant renal or hepatic impairment unless specifically directed by a physician.